Glycophos

Glycophos is a sodium glycerophosphate pentahydrate solution for injection, supplied as a sterile intravenous preparation. It contains the active ingredient sodium glycerophosphate pentahydrate and is marketed in the European Union as a prescription‑only product. The formulation provides both phosphate and sodium ions, supporting metabolic processes that require phosphate. Glycophos is administered by healthcare professionals in clinical settings to address phosphate depletion and related electrolyte disturbances.

Glycophos is indicated for the correction of low phosphate levels and associated electrolyte imbalances in patients who cannot receive oral supplementation. It is commonly used in hospital settings for individuals with hypophosphatemia due to renal loss, critical illness, or postoperative states.

- Treatment of hypophosphatemia caused by renal tubular disorders. - Management of phosphate depletion during prolonged parenteral nutrition. - Correction of electrolyte imbalance in patients undergoing major surgery. - Support for patients with severe burns or trauma who have increased phosphate demand. - Adjunct therapy for metabolic alkalosis when phosphate repletion is required.

Intravenous administration of Glycophos may be associated with a range of adverse reactions, most of which are mild and reversible.

Common: - Transient hyperphosphatemia. - Mild nausea or vomiting. - Local irritation at the injection site. - Temporary increase in serum sodium.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Acute renal failure in patients with pre‑existing kidney impairment. - Anaphylactic or severe hypersensitivity reactions.

Before using Glycophos, clinicians should evaluate patient history and laboratory values to minimize the risk of complications.

- Verify serum phosphate, calcium, and renal function before infusion. - Adjust dose in patients with chronic kidney disease or renal insufficiency. - Monitor electrolytes and acid‑base status during and after administration. - Use cautiously in individuals with heart failure or fluid overload. - Avoid rapid infusion rates that may cause cardiovascular instability. - Discontinue if signs of severe hyperphosphatemia develop.

Glycophos can interact with other medications or solutions that affect phosphate or calcium balance.

Avoid: - Calcium‑containing intravenous solutions administered simultaneously. - Loop diuretics that increase urinary phosphate loss.

Use with caution: - Vitamin D analogues that enhance intestinal phosphate absorption. - Antacids containing aluminum or magnesium, which may alter phosphate metabolism. - Parathyroid hormone analogues that affect calcium‑phosphate homeostasis.